Results for "consumer data right"
451-460 of 560 results for 'consumer data right'
Australia's foreign investment regime - Budget changes
The Australian Government flagged a number of changes to Australias foreign investment regime in the 2017 Budget In a welcome development the changes seek to simplify an otherwise complex regime and encourage foreign investment in Australia Partner Wendy Rae and Associate Nick Kefalianos examine the ...
Four key ways technology will help companies meet their decarbonisation goals
Companies know they have to change the way they operate if they're going to reach net zero by 2050. In this Insight, we explore four key ways technology can help meet decarbonisation goals, drawing on examples discussed in our recent webinar 'Leveraging technology to accelerate decarbonisation'. ...
Nucleus – corporate law developments: ASIC leadership changes and other updates
ASIC leadership changes; ASX advises constitution amendments for CHESS replacement, and launches consultation on oil and gas reporting amendments; ACCC teams up with UK and German competition regulators on merger control; Federal Court upholds record diesel emissions penalty ...
Dollars and sense: the evolution of executive remuneration practices
The need for robust executive remuneration frameworks is becoming increasingly important as companies tackle the challenges arising out of the COVID-19 pandemic, a heightened regulatory environment and the need to strike the right balance with executives to drive and reward conduct and performance t ...
Australian Financial Complaints Authority: a 'one-stop-shop' for financial dispute resolution
The new Australian Financial Complaints Authority is to replace each of the Superannuation Complaints Tribunal the Financial Ombudsman Service and the Credit and Investments Ombudsman in November 2018 ...
FIRB changes to note from 1 July 2023
In this Insight, we outline and comment on the New Register and corresponding reporting obligations. ...
Patent term extensions under siege: a new era of challenges for pharmaceutical patentees
A recent Federal Court decision has struck down a patent term extension granted to Novartis for its blockbuster heart failure drug Entresto. The decision in Novartis AG v Pharmacor Pty Limited follows a recent trend of successful challenges by generic pharmaceutical companies. ...
Interlocutory injunction refused based on 'doubtful' patent term extension
In the fight against patent infringement, challenging the validity of patent term extensions (PTEs) is increasingly becoming the weapon of choice for generic pharmaceutical companies. Since around the mid-2000s, patentees in pharmaceutical patent cases have typically been successful in bids for interlocutory injunctions, aiming to prevent the launch of generic products in Australia. The recent Biogen decision by the Federal Court is the latest in a trend of refusing interlocutory injunctions, and a clear indication the tide is turning. ...
ASIC's New Document Production Guidelines
ASIC has released its new Document Production Guidelines, which govern how it expects electronic and hard copy records to be produced in response to compulsory notices. ...